Trials / Unknown
UnknownNCT03249480
Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency
Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency: A Multicenter, Open-label, Phase IV Clinical Trial With Different Administration Dosage of PEG Somatropin
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 900 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 3 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
To Evaluate the safety and efficacy of PEG Somatropin in the treatment of children with growth hormone deficiency, as well as to study the dosage of PEG Somatropin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PEG-somatropin | 30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks. |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2017-08-01
- First posted
- 2017-08-15
- Last updated
- 2017-08-15
Locations
28 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03249480. Inclusion in this directory is not an endorsement.